Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims

1. (Currently amended) A compound of formula I



I

wherein:

A = CR^1 or N,

B = CR^2 or N,

D = CR^3 or N,

E = CR^4 or N and

F = CR^5 or N;

and the maximum number of nitrogen atoms amongst A, B, D, E, and F is two;

~~where m = 1-3 and n = 1-3~~ where m = 1 and n = 2;

~~and excluding all compounds where m = n = 2;~~

where each R^1, R^2, R^3, R^4 and R^5 is independently selected from F, Cl, Br, I, nitro, cyano, CF_3, $-NR^6R^7$, $-NR^6C(=O)R^7$, $-NR^6C(=O)NR^7R^8$, $-NR^6C(=O)OR^7$, $-OR^6$, $-OC(=O)R^6$, $-OC(=O)OR^6$, $-OC(=O)NR^6R^7$, $-OC(=O)SR^6$, $-C(=O)OR^6$, $-C(=O)R^6$, $-C(=O)NR^6R^7$, $-SR^6$, $-S(=O)R^6$, and a substituent from the definition of R^6;

each R^6, R^7, and R^8 is independently selected from H, straight chain or branched $(C_1$-$C_8)$alkyl, straight chain or branched $(C_2$-$C_8)$alkenyl, straight chain or branched $(C_2$-$C_8)$alkynyl, $(C_3$-$C_8)$cycloalkyl, $(C_4$-$C_8)$cycloalkenyl, 3-8 membered heterocycloalkyl, $(C_5$-$C_{11})$bicycloalkyl, $(C_7$-$C_{11})$bicycloalkenyl, 5-11 membered heterobicycloalkyl, 5-11 membered heterobicycloalkenyl, $(C_6$-$C_{11})$ aryl, and 5-12 membered heteroaryl; wherein each R^6, R^7, and R^8 is optionally substituted with from one to six substituents, independently selected from F, Cl, Br, I, nitro, cyano, CF_3, $-NR^9R^{10}$, $-NR^9C(=O)R^{10}$, $-NR^9C(=O)NR^{10}R^{11}$, $-NR^9C(=O)OR^{10}$, $-NR^9S(=O)_2R^{10}$, $-NR^9S(=O)_2NR^{10}R^{11}$, $-OR^9$, $-OC(=O)R^9$, $-OC(=O)OR^9$,

$-OC(=O)NR^9R^{10}$, $-OC(=O)SR^9$, $-C(=O)OR^9$, $-C(=O)R^9$, $-C(=O)NR^9R^{10}$, $-SR^9$, $-S(=O)R^9$, $-S(=O)_2R^9$, $-S(=O)_2NR^9R^{10}$ and R^9;

or R^1 and R^2, or R^2 and R^3, or R^3 and R^4, or R^4 and R^5, may form another 6-membered aromatic or heteroaromatic ring sharing A and B, or B and D, or D and E, or E and F, respectively, and may be optionally substituted with from one to four substituents independently selected from the group of radicals set forth in the definition of R^6, R^7 and R^8 above;

each R^9, R^{10} and R^{11} is independently selected from H, straight chain or branched $(C_1$-$C_8)$alkyl, straight chain or branched $(C_2$-$C_8)$alkenyl, straight chain or branched $(C_2$-$C_8)$alkynyl, $(C_3$-$C_8)$cycloalkyl, $(C_4$-$C_8)$cycloalkenyl, 3-8 membered heterocycloalkyl, $(C_5$-$C_{11})$bicycloalkyl, $(C_7$-$C_{11})$bicycloalkenyl, 5-11 membered heterobicycloalkyl, (5-11 membered) heterobicycloalkenyl, $(C_6$-$C_{11})$ aryl or 5-12 membered heteroaryl; wherein each R^9, R^{10} and R^{11} is optionally substituted with from one to six substituents independently selected from F, Cl, Br, I, nitro, cyano, CF_3, $-NR^{12}R^{13}$, $-NR^{12}C(=O)R^{13}$, $-NR^{12}C(=O)NR^{13}R^{14}$, $-NR^{12}C(=O)OR^{13}$, $-NR^{12}S(=O)_2R^{13}$, $-NR^{12}S(=O)_2NR^{13}R^{14}$, $-OR^{12}$, $-OC(=O)R^{12}$, $-OC(=O)OR^{12}$, $-OC(=O)NR^{12}R^{13}$, $-OC(=O)SR^{12}$, $-C(=O)OR^{12}$, $-C(=O)R^{12}$, $-C(=O)NR^{12}R^{13}$, $-SR^{12}$, $-S(=O)R^{12}$, $-S(=O)_2R^{12}$, $-S(=O)_2NR^{12}R^{13}$ and R^{12};

each R^{12}, R^{13}, and R^{14} is independently selected from H, straight chain or branched $(C_1$-$C_8)$alkyl, straight chain or branched $(C_2$-$C_8)$alkenyl, straight chain or branched $(C_2$-$C_8)$alkynyl, $(C_3$-$C_8)$cycloalkyl, $(C_4$-$C_8)$cycloalkenyl, 3-8 membered heterocycloalkyl, $(C_5$-$C_{11})$bicycloalkyl, $(C_7$-$C_{11})$bicycloalkenyl, 5-11 membered heterobicycloalkyl, 5-11 membered heterobicycloalkenyl, $(C_6$-$C_{11})$ aryl and (5-12 membered) heteroaryl;

or an enantiomeric, diastereomeric, or tautomeric isomer thereof or a and pharmaceutically acceptable salt thereof.

Claim 2. (Currently amended) A compound according to claim 1 wherein one or two of A, B, D or E is N; or a pharmaceutically acceptable salt thereof.

Claim 3. (Currently amended) A compound according to claim 1 wherein A and B are both N; or a pharmaceutically acceptable salt thereof.

Claim 4. (Currently amended) A compound according to claim 1 wherein A and E are both N; or a pharmaceutically acceptable salt thereof.

Claim 5. (Currently amended) A compound according to claim 1 wherein B and E are both N; or a pharmaceutically acceptable salt thereof.

Claim 6. (Currently amended) A compound according to claim 1wherein one of A, B or E is N; or a pharmaceutically acceptable salt thereof.

Claim 7. (Currently amended) A compound according to claim 1 wherein one of A or B is N; or a pharmaceutically acceptable salt thereof.

Claim 8. (Currently amended) A compound according to claim 1 wherein each R^1, R^2, R^3, R^4 and R^5 is independently selected from H, halo, $(C_1$-$C_6)$alkyl, $(C_1$-$C_6)$alkoxy, $(C_1$-$C_6)$fluoroalkyl, cyano, $(C_1$-$C_6)$alkoxycarbonyl; phenyl substituted or unsubstituted with halo, $(C_1$-$C_6)$alkyl, $(C_1$-$C_6)$alkoxy, $(C_1$-$C_6)$fluoroalkyl; and heteroaryl; or where any one of the R^1 and R^2, or R^2 and R^3, or R^3 and R^4, or R^4 and R^5 pairs located on adjacent carbon atoms join to form an unsaturated (C_4)alkylene bridge; or a pharmaceutically acceptable salt thereof.

Claims 9. to 13 (Canceled)

Claim 14. (Currently amended) A compound according to claim 1 selected from the group consisting of:

4-(5-Bromo-pyridin-3-yl)-1,4-diaza-bicyclo[3.2.1]octane;

4-(5-Phenyl-pyridin-3-yl)-1,4-diaza-bicyclo[3.2.1]octane;

4-Pyridin-2-yl-1,4-diaza-bicyclo[3.2.1]octane;

4-Pyridin-3-yl-1,4-diaza-bicyclo[3.2.1]octane:

4-Pyridin-4-yl-1,4-diaza-bicyclo[3.2.1]octane:

4-(5-Phenyl-pyridazin-3-yl)-1,4-diaza-bicyclo[3.2.1]octane;

4-(5-Bromo-pyridin-2-yl)-1,4-diaza-bicyclo[3.2.1]octane;

4-(6-Phenyl-pyridazin-3-yl)-1,4-diaza-bicyclo[3.2.1]octane;

4-Pyrazin-2-yl-1,4-diaza-bicyclo[3.2.1]octane;

4-Pyrimidin-5-yl-1,4-diaza-bicyclo[3.2.1]octane;

4-(5-Chloro-pyridin-3-yl)-1,4-diaza-bicyclo[3.2.1]octane;

4-[5-(3-Trifluoromethyl-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.2.1]octane;

4-(3-Bromo-phenyl)-1,4-diaza-bicyclo[3.2.1]octane;

5-(1,4-Diaza-bicyclo[3.2.1]oct-4-yl)-nicotinonitrile;

4-(5-Trifluoromethyl-pyridin-3-yl)-1,4-diaza-bicyclo[3.2.1]octane;

4-[5-(2-Trifluoromethyl-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.2.1]octane;

4-[5-(4-Trifluoromethyl-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.2.1]octane;

4-[5-(2-Fluoro-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.2.1]octane;

4-[5-(4-Fluoro-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.2.1]octane;

3-(1,4-Diaza-bicyclo[3.2.1]oct-4-yl)-quinoline;

4-(3-Trifluoromethyl-pyridin-2-yl)-1,4-diaza-bicyclo[3.2.1]octane;

4-(6-Methoxy-pyridin-2-yl)-1,4-diaza-bicyclo[3.2.1]octane;

4-[5-(2-Methoxy-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.2.1]octane;

4-[5-(3-Methoxy-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.2.1]octane;

4-(5-o-Tolyl-pyridin-3-yl)-1,4-diaza-bicyclo[3.2.1]octane;

5-(1,4-Diaza-bicyclo[3.2.1]oct-4-yl)-nicotinic acid ethyl ester;

4-(5-Chloro-pyridin-2-yl)-1,4-diaza-bicyclo[3.2.1]octane;

4-(6-Methyl-pyridin-3-yl)-1,4-diaza-bicyclo[3.2.1]octane;

4-[5-(3-Trifluoromethyl-phenyl)-pyridin-2-yl]-1,4-diaza-bicyclo[3.2.1]octane;

4-[5-(4-Chloro-phenyl)-pyridin-2-yl]-1,4-diaza-bicyclo[3.2.1]octane;

4-(5-o-Tolyl-pyridin-2-yl)-1,4-diaza-bicyclo[3.2.1]octane;

4-[5-(3-Chloro-phenyl)-pyridin-2-yl]-1,4-diaza-bicyclo[3.2.1]octane;

4-[5-(3-Fluoro-phenyl)-pyridin-2-yl]-1,4-diaza-bicyclo[3.2.1]octane;

4-[5-(4-Chloro-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.2.1]octane;

4-[5-(2,4-Dichloro-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.2.1]octane;

4-[5-(3-Chloro-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.2.1]octane;

4-(5-p-Tolyl-pyridin-3-yl)-1,4-diaza-bicyclo[3.2.1]octane;

4-[5-(4-Methoxy-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.2.1]octane;

4-(5-Methoxy-pyridin-3-yl)-1,4-diaza-bicyclo[3.2.1]octane;

5-(1,4-Diaza-bicyclo[3.2.1]oct-4-yl)-[3,4']bipyridinyl; and

4-(2-Methyl-5-trifluoromethyl-pyridin-3-yl)-1,4-diaza-bicyclo[3.2.1]octane; or a pharmaceutically acceptable salt thereof.

Claim 15. (Currently amended) A compound according to claim 1 selected from the group consisting of:

(+)-4-(5-Bromo-pyridin-3-yl)-1,4-diaza-bicyclo[3.2.1]octane;

(+)-4-(5-Phenyl-pyridin-3-yl)-1,4-diaza-bicyclo[3.2.1]octane;

(+)-4-Pyridin-2-yl-1,4-diaza-bicyclo[3.2.1]octane;

(+)-4-Pyridin-3-yl-1,4-diaza-bicyclo[3.2.1]octane;

(+)-4-Pyridin-4-yl-1,4-diaza-bicyclo[3.2.1]octane;

(+)-4-(5-Phenyl-pyridazin-3-yl)-1,4-diaza-bicyclo[3.2.1]octane;

(+)-4-(5-Bromo-pyridin-2-yl)-1,4-diaza-bicyclo[3.2.1]octane;

(+)-4-(6-Phenyl-pyridazin-3-yl)-1,4-diaza-bicyclo[3.2.1]octane;

(+)-4-Pyrazin-2-yl-1,4-diaza-bicyclo[3.2.1]octane;

(+)-4-Pyrimidin-5-yl-1,4-diaza-bicyclo[3.2.1]octane;

(+)-4-(5-Chloro-pyridin-3-yl)-1,4-diaza-bicyclo[3.2.1]octane;

(+)-4-[5-(3-Trifluoromethyl-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.2.1]octane;

(+)-4-(3-Bromo-phenyl)-1,4-diaza-bicyclo[3.2.1]octane;

(+)-5-(1,4-Diaza-bicyclo[3.2.1]oct-4-yl)-nicotinonitrile;

(+)-4-(5-Trifluoromethyl-pyridin-3-yl)-1,4-diaza-bicyclo[3.2.1]octane;

(+)-4-[5-(2-Trifluoromethyl-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.2.1]octane;

(+)-4-[5-(4-Trifluoromethyl-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.2.1]octane;

(+)-4-[5-(2-Fluoro-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.2.1]octane;

(+)-4-[5-(4-Fluoro-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.2.1]octane;

(+)-3-(1,4-Diaza-bicyclo[3.2.1]oct-4-yl)-quinoline;

(+)-4-(3-Trifluoromethyl-pyridin-2-yl)-1,4-diaza-bicyclo[3.2.1]octane;

(+)-4-(6-Methoxy-pyridin-2-yl)-1,4-diaza-bicyclo[3.2.1]octane;

(+)-4-[5-(2-Methoxy-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.2.1]octane;

(+)-4-[5-(3-Methoxy-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.2.1]octane;

(+)-4-(5-o-Tolyl-pyridin-3-yl)-1,4-diaza-bicyclo[3.2.1]octane;

(+)-5-(1,4-Diaza-bicyclo[3.2.1]oct-4-yl)-nicotinic acid ethyl ester;

(+)-4-(5-Chloro-pyridin-2-yl)-1,4-diaza-bicyclo[3.2.1]octane;

(+)-4-(6-Methyl-pyridin-3-yl)-1,4-diaza-bicyclo[3.2.1]octane;

(+)-4-[5-(3-Trifluoromethyl-phenyl)-pyridin-2-yl]-1,4-diaza-bicyclo[3.2.1]octane;

(+)-4-[5-(4-Chloro-phenyl)-pyridin-2-yl]-1,4-diaza-bicyclo[3.2.1]octane;

(+)-4-(5-o-Tolyl-pyridin-2-yl)-1,4-diaza-bicyclo[3.2.1]octane;

(+)-4-[5-(3-Chloro-phenyl)-pyridin-2-yl]-1,4-diaza-bicyclo[3.2.1]octane;

(+)-4-[5-(3-Fluoro-phenyl)-pyridin-2-yl]-1,4-diaza-bicyclo[3.2.1]octane;

(+)-4-[5-(4-Chloro-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.2.1]octane;

(+)-4-[5-(2,4-Dichloro-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.2.1]octane;

(+)-4-[5-(3-Chloro-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.2.1]octane;

(+)-4-(5-p-Tolyl-pyridin-3-yl)-1,4-diaza-bicyclo[3.2.1]octane;

(+)-4-[5-(4-Methoxy-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.2.1]octane;

(+)-4-(5-Methoxy-pyridin-3-yl)-1,4-diaza-bicyclo[3.2.1]octane;

(+)-5-(1,4-Diaza-bicyclo[3.2.1]oct-4-yl)-[3,4']bipyridinyl; and

(+)-4-(2-Methyl-5-trifluoromethyl-pyridin-3-yl)-1,4-diaza-bicyclo[3.2.1]octane; or a pharmaceutically acceptable salt thereof.

Claim 16. (Currently amended) A compound according to claim 1 selected from the group consisting of:

(-)-4-(5-Bromo-pyridin-3-yl)-1,4-diaza-bicyclo[3.2.1]octane;

(-)-4-(5-Phenyl-pyridin-3-yl)-1,4-diaza-bicyclo[3.2.1]octane;

(-)-4-Pyridin-2-yl-1,4-diaza-bicyclo[3.2.1]octane;

(-)-4-Pyridin-3-yl-1,4-diaza-bicyclo[3.2.1]octane;

(-)-4-Pyridin-4-yl-1,4-diaza-bicyclo[3.2.1]octane;

(-)-4-(5-Phenyl-pyridazin-3-yl)-1,4-diaza-bicyclo[3.2.1]octane;

(-)-4-(5-Bromo-pyridin-2-yl)-1,4-diaza-bicyclo[3.2.1]octane;

(-)-4-(6-Phenyl-pyridazin-3-yl)-1,4-diaza-bicyclo[3.2.1]octane;

(-)-4-Pyrazin-2-yl-1,4-diaza-bicyclo[3.2.1]octane;

(-)-4-Pyrimidin-5-yl-1,4-diaza-bicyclo[3.2.1]octane;

(-)-4-(5-Chloro-pyridin-3-yl)-1,4-diaza-bicyclo[3.2.1]octane;

(-)-4-[5-(3-Trifluoromethyl-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.2.1]octane;

(-)-4-(3-Bromo-phenyl)-1,4-diaza-bicyclo[3.2.1]octane;

(-)-5-(1,4-Diaza-bicyclo[3.2.1]oct-4-yl)-nicotinonitrile;

(-)-4-(5-Trifluoromethyl-pyridin-3-yl)-1,4-diaza-bicyclo[3.2.1]octane;

(-)-4-[5-(2-Trifluoromethyl-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.2.1]octane;

(-)-4-[5-(4-Trifluoromethyl-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.2.1]octane;

(-)-4-[5-(2-Fluoro-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.2.1]octane;

(-)-4-[5-(4-Fluoro-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.2.1]octane;

(-)-3-(1,4-Diaza-bicyclo[3.2.1]oct-4-yl)-quinoline;

(-)-4-(3-Trifluoromethyl-pyridin-2-yl)-1,4-diaza-bicyclo[3.2.1]octane;

(-)-4-(6-Methoxy-pyridin-2-yl)-1,4-diaza-bicyclo[3.2.1]octane;

(-)-4-[5-(2-Methoxy-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.2.1]octane;

(-)-4-[5-(3-Methoxy-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.2.1]octane;

(-)-4-(5-o-Tolyl-pyridin-3-yl)-1,4-diaza-bicyclo[3.2.1]octane;

(-)-5-(1,4-Diaza-bicyclo[3.2.1]oct-4-yl)-nicotinic acid ethyl ester;

(-)-4-(5-Chloro-pyridin-2-yl)-1,4-diaza-bicyclo[3.2.1]octane;

(-)-4-(6-Methyl-pyridin-3-yl)-1,4-diaza-bicyclo[3.2.1]octane;

(-)-4-[5-(3-Trifluoromethyl-phenyl)-pyridin-2-yl]-1,4-diaza-bicyclo[3.2.1]octane;

(-)-4-[5-(4-Chloro-phenyl)-pyridin-2-yl]-1,4-diaza-bicyclo[3.2.1]octane;

(-)-4-(5-o-Tolyl-pyridin-2-yl)-1,4-diaza-bicyclo[3.2.1]octane;

(-)-4-[5-(3-Chloro-phenyl)-pyridin-2-yl]-1,4-diaza-bicyclo[3.2.1]octane;

(-)-4-[5-(3-Fluoro-phenyl)-pyridin-2-yl]-1,4-diaza-bicyclo[3.2.1]octane;

(-)-4-[5-(4-Chloro-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.2.1]octane;

(-)-4-[5-(2,4-Dichloro-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.2.1]octane;

(-)-4-[5-(3-Chloro-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.2.1]octane;

(-)-4-(5-p-Tolyl-pyridin-3-yl)-1,4-diaza-bicyclo[3.2.1]octane;

(-)-4-[5-(4-Methoxy-phenyl)-pyridin-3-yl]-1,4-diaza-bicyclo[3.2.1]octane;

(-)-4-(5-Methoxy-pyridin-3-yl)-1,4-diaza-bicyclo[3.2.1]octane;

(-)-5-(1,4-Diaza-bicyclo[3.2.1]oct-4-yl)-[3,4']bipyridinyl; and

(-)-4-(2-Methyl-5-trifluoromethyl-pyridin-3-yl)-1,4-diaza-bicyclo[3.2.1]octane; or a pharmaceutically acceptable salt thereof.

Claims 17. to 30. (Canceled)

Claim 31. (Currently amended) A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof and pharmaceutically acceptable carrier.

Claim 32. (Canceled)